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Abstract Renal mesangial cells express group II phospholipase 
Az in response to two principal classes of activating signals that 
may interact in a synergistic fashion. These two groups of activa- 
tors comprise inflammatory cytokines uch as interleukin-ll~ (IL- 
1~) and tumor necrosis factor-~ (TNF~) and agents that elevate 
cellular levels of cAMP such as forskolin, an activator of adenyi- 
ate cyclase. Using pyrrolidine dithiocarbamate (PDTC), a potent 
inhibitor of nuclear factor NF~B, we determined its role in cyto- 
kine - and cAMP - triggered group II PLA 2 expression. Micro- 
molar amounts of PDTC suppress the IL-1 I3- and TNF~-dependent, 
but not the forskolin-stimulated group II PLA 2 activity in me- 
sangial cells. Furthermore, PDTC inhibited the increase of group 
II PLA 2 mRNA steady state levels in response to IL-I~ and 
TNF~, while only marginally affecting forskolin-induced PLA 2 
mRNA levels. Our data suggest that NF~cB activation is an 
essential component of the cytokine signalling pathway responsi- 
ble for group II PLA 2 gene regulation and that cAMP triggers 
a separate signalling cascade not involving NFrcB. These observa- 
tions may provide a basis to study the underlying mechanisms 
involved in the regulation of group II PLAz geoe expression. 
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1. Introduction 
Phospholipase A2 (PLA2) comprises a group of lipolytic en- 
zymes that specifically release fatty acids, often arachidonic 
acid, from the sn-2 position of membrane phospholipids for 
production of important lipid mediators uch as eicosanoids 
and platelet activating factor [1,2]. It has become evident hat 
PLA2s are a heterogenous family of enzymes that can be classi- 
fied into two classes. A class of high molecular weight PLA2s 
of 60-110 kDa, also referred to as cytosolic PLA2s or cPLA2s, 
and a class of low molecular weight PLA2s of 14 kDa referred 
to as secretory PLA2s or sPLA2s. Members of both classes from 
human and rat sources have recently been cloned [2]. Based on 
their primary structure, the sPLAzs are further classified into 
two groups [3]. Mammalian group I PLA2 comprises the pan- 
creatic type of PLA2 and mammalian group II PLA2 is synthe- 
sized and secreted from many cell types and is believed to play 
a role in the initiation and propagation of inflammatory proc- 
esses (for review see [4]). 
Two potent proinflammatory c tokines, IL-lfl and TNFcc, 
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have been shown to induce the synthesis and secretion of group 
II PLA2 in rabbit and rat chondrocytes [5,6], human synovial 
cells [7], rat mesangial cells [8,9], MDCK cells [10] and other 
cell systems [2]. The cytokine effect is blocked by actinomycin 
D and cycloheximide, thus demonstrating a requirement for 
both transcription and de novo protein synthesis. This is con- 
firmed by the observation that IL-lfl and TNFc~ increase the 
level of mRNA for group II PLA2 in rabbit articular chondro- 
cytes [11,12], rat astrocytes [13], rat mesangial cells [14,15], rat 
vascular smooth muscle cells [16] and human hepatoma cells 
[17]. Recently, we demonstrated anincreased secretion of group 
II PLA2 in rat vascular smooth muscle cells [18] and rat me- 
sangial cells [19,20] in response to cAMP-elevating agents. Fur- 
thermore, forskolin, an activator of adenylate cyclase, synergis- 
tically interacts with IL-lfl to increase group II PLA2 mRNA 
levels in mesangial cells [21]. 
At present, little is known about the mechanism(s) involved 
in the upregulation ofgroup II PLA 2 mRNA levels. In addition, 
the nuclear factor(s) which may be important for the regulation 
of the group II PLA2 gene are poorly defined. In the present 
study we have used pyrrolidine dithiocarbamate, an inhibitor 
of NF~cB activation, to determine whether NFxB is required for 
cytokine- and cAMP- induced group II PLA 2 gene transcrip- 
tion. 
2. Materials and methods 
2.1. Cell culture 
Rat mesangial cells were cultured as described previously [22]. In a 
second step, single cells were cloned by limited dilution using 96-mi- 
crowell plates. Clones with apparent mesangial cell morphology were 
used for further processing. The cells exhibited the typical stellate mor- 
phology. Moreover, there was positive staining for the intermediate 
filaments desmin and vimentin, which are considered to be specific for 
myogenic ells, positive staining for Thy 1.1 antigen, negative staining 
for the factor VIII-related antigen and cytokeratin, excluding endothe- 
lial and epithelial contamination, respectively. The generation of inosi- 
tol trisphosphate upon activation of the angiotensin II AT~ receptor 
was used as a functional criterion for characterizing the cloned cell line. 
The cells were grown in RPM1 1640 supplemented with 10% fetal calf 
serum, penicillin (100 units/ml), streptomycin (100 ¢t/ml) and bovine 
insulin at 0.66 units/ml (Sigma). For the experiments passages 6 16 of 
mesangial cell were used. 
2.2. Phospholipase A 2 assay 
Phospholipase A 2 activity was determined with [1-14C]oleate-labelled 
Escherichia coli as substrate as described previously [23]. The substrate 
was prepared by growing E. coli in the presence of [1-'4C]oleate, fol- 
lowed by autoclaving to inactivate ndogenous phospholipases. Over 
95% of the label incorporated by E. coli was in phospholipid and, as 
demonstrated byhydrolysis with snake venom (CrotaIus adamanteus), 
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more than 95% of the [1-~4C]oleate was in the sn-2 position of the 
phospholipids. Assay mixtures (1.0 ml) contained 100 mM Tris-HC1 
buffer (pH 7.0), 1 mM CaCI2, 2.5 x 108 [1-HC]oleate-labelled E. coli (5 
nmol of phospholipids, 5000-8000 cpm) and the enzyme to be tested 
at a dilution producing 5% substrate hydrolysis. Reaction mixtures 
were incubated for 1 h at 37 ° C in a shaking water bath. The reaction 
was stopped by the addition of 5 ml of propan-2-ol/n-heptan/l M 
H2SO 4 (40:10:1 v/v) followed by 2 ml of heptane and 3 ml of water. 
After vigorous haking and phase separation, a portion (2.5 ml) of the 
upper phase was passed over a column of silicic acid (3.5 x 0.5 cm). Free 
[l-~4C]oleic acid was quantitatively eluted with 1 ml of ethylacetate. 
Radioactivity was determined in a scintillation counter. Phospholipase 
A2 activity is expressed as [1-t4C]oleate radioactivity released by 100/~1 
of cell culture supernatant. 
2.3. Northern blot ananlysis 
Confluent mesangial cells were washed twice with PBS and incubated 
in DMEM, supplemented with 0.1 mg/ml of fatty acid-free bovine 
serum albumin, with or without agents for the indicated time periods. 
Cells were washed twice with PBS and harvested using a rubber police- 
man. Total cellular RNA was extracted from the cell pellets using the 
guanidinium thiocyanate/cesium chloride method [24]. Samples of 20 
Hg RNA were separated on 1% agarose gels containing 0.66 M formal- 
dehyde prior to the transfer to gene screen membranes (New England 
Nuclear). After UV-crosslinking and prehybridization for 2 h, the fil- 
ters were hybridized for 16 18 h to a 32p-labelled EeoRI/HindII I -cDNA 
insert from p139-1 coding for rat group II phospholipase A2 [25]. To 
correct for variation in RNA amount, the PLA, probe was stripped 
with boiling 0.1 x SSC/1% SDS and the blots were rehybridized to the 
s2p-labelled EeoRl genomic DNA-fragment coding for 28S ribosomal 
RNA or the BamHI/SalI cDNA insert from clone pEX 6 coding for 
human fl-actin. DNA-probes (0.5 1 x 10 6 dpm/ml) were radioactively 
labelled with [B:p]dATP by random priming (Boehringer-Mannheim). 
Hybridization reactions were performed in 50% (v/v) formamide, 5x 
SSC, 5 x Denhardt's solution, 1% (w/v) SDS, 10% (w/v) dextran sulfate 
and 100 ,ug/ml salmon sperm DNA. Filters were washed 3 times in 2x 
SSC/0.1%SDS at room temperature for 15 min, and then 2 times in 0.2 x 
SSC/I% SDS at 65°C for 30 min. Filters were exposed for 2448 h to 
Kodak X-Omat XAR-film using intensifying screens. 
2.4. Chemicals 
Recombinant human IL-lfl was generously supplied by Dr. Klaus 
Vosbeck, Ciba-Geigy Ltd., Basel, Switzerland; recombinant human 
TNFc~ was from Boehringer-Mannheim. The genomic lone coding for 
28S ribosomal RNA was kindly provided by Dr. Thomas Geiger, Ciba- 
Geigy Ltd., Basel, Switzerland; the cDNA-clone pEX 6, coding for 
human fl-actin was a gift from Dr. U. Aebi, Basel, Switzerland. PDTC 
was from Sigma, Buchs, Switzerland; forskolin was from Calbiochem, 
Lucerne, Switzerland. [l-~4C]Oleic acid and [32p]dATP (specific activity 
3000 Ci/mmol) were from Amersham, Diibendorf, Switzerland. Nylon 
membranes (Gene Screen) were purchased from DuPont de Nemours 
Int., Regensdorl, Switzerland. Cell culture media and nutrients were 
fi'om Gibco BRL, Basel, Switzerland and other chemicals used were 
either from Merck, Darmstadt, Germany or Fluka, Basel, Switzerland. 
3. Results 
Incubation of mesangial cells for 24 h with either IL-lf l  (1 
nM), TNF~ (1 riM) or forskolin (10/tM) increased PLA 2 activ- 
ity secreted by mesangial cells as shown in Table 1. Stimulation 
with IL-lf l  increased PLA, activity about 13-fold, whereas 
TNF~ was less potent, enhancing PLA 2 activity only about 
5-fold. Forskolin induced PLA2 activity by about 4-fold. The 
increase in PLA~ activity is preceeded by an increase in steady 
state mRNA levels for sPLA 2 as shown in the time course 
experiments in Fig. 1. Mesangial cells were incubated for vari- 
ous time points ranging from 2 h up to 24 h with IL-lf l  (1 nM), 
TNF~ (1 nM) or forskolin (10/,tM), respectively. Total cellular 
RNA was extracted and examined by Northern blot analysis. 
Stimulation with IL-lf l  or TNFc~ (1 nM) resulted in a rapid 
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Table 1 
Effects of PDTC on IL-lfl, TNFct and forskolin-stimulated group 11 
PLA 2 secretion from mesangial cells 
Addition PLA~ secretion 
(cpm/100 ktl) 
Control 441 + 31 
PDTC (100/zM) 614 + 38 
IL-lfl (1 nMl 5749 + 262 
TNF~ (1 nM) 2088 + 148 
Forsk (10 HM) 1611 _+ 75 
IL-lfl (l nM) +PDTC (100//M) 1260 + 156"** 
IL-lfl (1 nM) +PDTC (50//M) 1751 _+ 91"** 
IL-lfl (1 nM) +PDTC (20/IM) 4785 + 175" 
TNF~ (1 nM) +PDTC (100//M) 622 _+ 53*** 
TNF~ (1 nM) +PDTC (50/IM) 939 + 21"** 
TNF~ (1 nM) +PDTC (20/.tM) 1720 + 150 
Forsk (10HM) +PDTC (100 ltM) 1546 + 140 
Forsk (10 ktM) +PDTC (50/,tM) 1568 + 282 
Forsk ( 10/,tM) + PDTC (20/IM) 1823 + 83 
Confluent mesangial cells were incubated with the indicated concentra- 
tions of IL-lfl, TNF~, forskolin (Forsk) and PDTC for 24 h. Thereaf- 
ter, the medium was withdrawn and PLA_~ activity determined as de- 
scribed in section 2. Results are means + S.D. (n = 4). Significant differ- 
ences from the corresponding control stimulation in the absence of 
PDTC: *P < 0.05; ***P < 0.001. by Student's t-test. 
accumulation of group I! PLA~ mRNA levels detectable al- 
ready 24  h post-stimulation (Fig. lA  and B). Upon incubation 
of mesangial cells with forskolin (10 /,tM) group 11 PLA, 
mRNA levels could be detected already at 2 h after stimulation 
(Fig. 1C). Simultaneous incubation with NFxB inhibitor PDTC 
dose-dependently inhibited PLA 2 activity in response to IL-lf l  
and TNFcx, but not to forskolin (Table 1). Half-maximal inhibi- 
tion of IL-lfl- and TNFc~-stimulated PLA2-activity was ob- 
served at about 39/ IM and 46/ IM of PDTC, respectively. In 
contrast, forskolin-induced PLA: activity was virtually not af- 
fected by PDTC up to concentrations of 100/tM (Table 1). In 
order to determine whether the inhibition of the IL-lf l and 
TNF~-dependent s imulation by PDTC was due to the down- 
regulation of group II PLA: steady-state mRNA levels, we 
performed Northern blot analysis. Total cellular RNA was 
isolated from mesangial cells after coincubation with IL-lf l  (1 
nM), TNF~ (1 nM) or forskolin (10/,tM) in the presence of 100 
/IM PDTC. The data in Fig. 2 demonstrate down-regulation of
group II PLA2 mRNA levels upon simultaneous incubation of 
cells with cytokines and PDTC. Coincubation of mesangial 
cells with IL-lf l (Fig. 2A) or TNFc~ (Fig. 2B) with PDTC causes 
an almost complete suppression of the induction of group II 
PLA2 mRNA levels after 6 h (lanes 4 in Fig. 2A and B) or 
results in a drastically reduced induction after a 12 h coincuba- 
tion period (lanes 6 in Fig. 2A and B). In contrast, PDTC did 
not or only sligthly attenuate group II PLA: mRNA increase 
observed after stimulation of cells with forskolin (Fig. 2C). 
4. Discussion 
Potent proinflammatory c tokines, such as IL-lf l  and TNF~, 
have been found to increase group II PLA2 gene expression in 
various cell-types [11-17]. We were the first to report that 
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cytokines uch as IL-lfl or TNFct as well as cAMP-elevating 
compounds are capable of inducing the synthesis and release 
of group II PLA 2 in cultured rat mesangial cells [8,9,19,20]. We 
have recently shown that IL-lfl dose-dependently increases 
group II PLA 2 mRNA levels in mesangial cells and that fors- 
kolin synergistically interacts with IL-lfl to increase group II 
PLA2 mRNA steady state levels [21]. These data suggest hat 
there exist at least two distinct activation mechanisms for the 
induction of group II PLA2, one is activated by cAMP and the 
other is triggered by cytokines uch as IL-lfl. 
Little is known about the underlying mechanism(s) of the 
up-regulation of group II PLA2 mRNA levels and about the 
transcription factor(s) which may be involved in the regulation 
of the group II PLA 2 gene. The control of transcription in 
response to inflammatory cytokines has been intensively stud- 
ied, and it has become clear that a number of ubiquitous tran- 
scription factors are involved in many different cellular sys- 
tems. Very prominent under these factors is NFxB a multi- 
subunit transcription factor that is activated in response to 
IL-lfl, TNFct, bacterial endotoxin and various other stimuli 
and plays a pivotal role in the development of the cellular 
immune and inflammatory responses [26]. NFxB is constitu- 
tively present in cells as a heterodimer, consisting of a p50 
DNA-binding subunit and a Rel A (p65) transactivating sub- 
unit. This NFxB complex is maintained in a latent cytoplasmic 
form by the physical association with an inhibitor IxB [26]. The 
mechanism leading to NFxB activation in not fully defined, but 
phosphorylation a d degradation of IxB seem to be the impor- 
tant steps in the activation process which causes dissociation 
of IxB from NFxB and nuclear translocation of NFxB with 
subsequent specific gene transcription [26]. In order to further 
clarify the basic mechanism of the induction of group II PLA2 
in mesangial cells by IL-lfl, TNF~ and cAMP, we evaluated 
whether the activation of NFxB participates in this process. 
For our experiments we took advantage of the fact that 
pyrrolidine dithiocarbamate efficiently suppresses the activa- 
tion of NFxB in stimulated cells, while leaving the DNA-bind- 
ing capacity of other transcription factors such as Sp-1, Oct 1 
and CREB unaffected [27]. Expression of the group II PLA 2 
gene by IL-lfl and TNF~ is strongly suppressed by PDTC in 
a dose-dependent fashion (Fig. 2A and B), suggesting that 
NFxB - probably in cooperation with other transcription fac- 
tors - is involved in the regulation of the group II PLA2 gene 
transcription i mesangial cells. In contrast, cAMP-triggered 
expression of the group II PLA2 gene is not affected by PDTC, 
indicating that cAMP activates other nuclear factors, most 
probably CREB, AP-2 or related proteins. This is particularly 
important because it has been shown for human myeloid cells 
that cAMP can activate NFxB [28]. The gene coding for rat 
group II PLA2 has been cloned [29-31] and 497 bp of the 
putative 5' flanking region have been sequenced [31]. Its in- 
volvement in the regulation of the group II PLA 2 gene by 
functional analysis remains to be demonstrated. However, 
screening of the proximal region of the potential promoter 
<___ 
Fig. 1. Time course of induction of group II PLA 2 mRNA in mesangial 
cells following stimulation with IL-l,8, TNF~ and forskolin. Mesangial 
cells were incubated with IL-lfl (1 nM) (A), TNF~ (1 nM) (B) or 
forskolin (10 ,uM) (C) for the indicated time periods. Total cellular 
RNA (20/.tg) was hybridized successively to 32p-labelled group II PLA2 
and fl-actin cDNA-probe as described in section 2. 
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fragment for consensus equences of possible cis-acting ele- 
ments reveals the presence of the sequence-motif 5'-GGGCT- 
TTTCC-3'  which is highly homologeous (in 8 out of 9 bases) 
to the consensus sequence 5' -GGGPuNNPyPyCC-3'  known to 
bind with high affinity the heterodimer of NFxB composed of 
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Fig. 2. (A) Effects of PDTC on IL-lfl-stimulated group II PLA 2 mRNA 
accumulation. Mesangial cells were incubated for 6 h with vehicle 
(control) (1), PDTC (100/IM) (2), IL-1]/(1 nM)(3), IL-lfl (1 nM) plus 
PDTC (100/IM) (4), or for 12 h with IL-lfl (l nM) (5) or IL-lfl (l nM) 
plus PDTC (100/IM) (6). (B) Effects of PDTC on TNF~-stimulated 
group II PLA 2 mRNA accumulation. Mesangial cells were incubated 
for 6 h with vehicle (control) (1), PDTC (100/2M) (2), TNFc~ (1 nM) 
(3), TNFc~ (1 nM) plus PDTC (100/~M) (4), or for 12 h with TNFc~ (1 
nM) (5) or TNF~ (1 nM) plus PDTC (100/.tM) (61. (C) Effects of PDTC 
on forskolin-stimulated group II PLA,_ mRNA accumulation. Me- 
sangial cells were incubated for 6 h with vehicle (control) (1), PDTC 
(100/~M) (2), forskolin (10,uM) (3), forskolin (10/~M) plus PDTC (100 
/IM) (4), or for 12 h with forskolin (10/IM) (5) or forskolin (10/IM) 
plus PDTC (100/.tM) (6). Total cellular RNA (20/.tg) was successively 
hybridized to 32p-labelled group II PLA2 and fl-actin cDNA probes as 
described in section 2. 
<____ 
subunits p50 and Rel A (p65) [26]. Preliminary data in our 
laboratory, obtained with electrophoretic mobility-shift assays 
using a radioactively labelled oligonucleotide containing the 
sequence derived from the group II PLA_, gene, give strong 
evidence that this potential cis-acting element is in fact involved 
in the binding of NFxB (G. Walker, D. Kunz and J. Pfeil- 
schifter, unpublished results). 
From data present in this study it is becoming obvious that 
the induction of PLA 2 activity in mesangial cells is regulated by 
multiple signalling cascades. These may acl alone or synergize 
with each other when stimulated in combination. It is clear 
from our results that PDTC can inhibit IL-lfl and TNFc~- 
stimulated PLA2 expression i  mesangial cells. Obviously IL-lfl 
and TNF~ use NFxB to trigger egulation of the group I1 PLA 2 
gene whereas cAMP activates the gene by transcription factors 
different from N DcB. Glomerular mesangial cells are a special- 
ized type of vascular smooth muscle cells participating in the 
regulation of the glomerular filtration rate. These cells are being 
increasingly recognized as important arget and effector cells 
in the pathogenesis of acute and chronic forms of renal dis- 
eases. In addition, there is substantial evidence that extracellu- 
lar group II PLA2 plays an important role in the pathogenesis 
of diverse inflammatory processes [4]. Therefore, to understand 
the basic mechanism of PLA 2 gene regulation is an essential 
prerequisite for the development of new pharmacological p- 
proaches for effective treatment of patients with chronic renal 
diseases. 
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